Medivir AB (publ) (STO:MVIR)
Sweden · Delayed Price · Currency is SEK 0.4470
-0.0050 (-1.11%)
At close: Feb 4, 2026
Medivir AB Revenue
Medivir AB had revenue of 900.00K SEK in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to 3.98M, down -42.54% year-over-year. In the year 2024, Medivir AB had annual revenue of 3.48M, down -54.36%.
Revenue (ttm)
3.98M
Revenue Growth
-42.54%
P/S Ratio
48.52
Revenue / Employee
388.40K
Employees
10
Market Cap
188.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.48M | -4.15M | -54.36% |
| Dec 31, 2023 | 7.63M | 3.23M | 73.16% |
| Dec 31, 2022 | 4.41M | -27.99M | -86.39% |
| Dec 31, 2021 | 32.39M | 11.96M | 58.56% |
| Dec 31, 2020 | 20.43M | 11.71M | 134.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| Sprint Bioscience AB | 50.03M |
| Bio-Works Technologies AB | 46.43M |
| Elicera Therapeutics AB | 13.70M |
| NextCell Pharma AB | 11.06M |
| Xintela AB | 2.96M |
| Karolinska Development AB | 1.74M |